RT Journal Article
SR Electronic
T1 Streptococcus species abundance in the gut is linked to subclinical coronary atherosclerosis in 8,973 participants from the SCAPIS cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.25.22275561
DO 10.1101/2022.05.25.22275561
A1 Sayols-Baixeras, Sergi
A1 Dekkers, Koen F
A1 Hammar, Ulf
A1 Baldanzi, Gabriel
A1 Lin, Yi-Ting
A1 Ahmad, Shafqat
A1 Nguyen, Diem
A1 Varotsis, Georgios
A1 Pita, Sara
A1 Nielsen, Nynne
A1 Eklund, Aron C.
A1 Holm, Jacob B
A1 Nielsen, H Bjørn
A1 Brunkwall, Louise
A1 Ottosson, Filip
A1 Nowak, Christoph
A1 Jönsson, Daniel
A1 Ericson, Dan
A1 Klinge, Björn
A1 Nilsson, Peter M
A1 Malinovschi, Andrei
A1 Lind, Lars
A1 Bergström, Göran
A1 Sundström, Johan
A1 Ärnlöv, Johan
A1 Engström, Gunnar
A1 Smith, J. Gustav
A1 Orho-Melander, Marju
A1 Fall, Tove
YR 2022
UL http://medrxiv.org/content/early/2022/05/25/2022.05.25.22275561.abstract
AB Coronary atherosclerosis is the main pathophysiological mechanism underlying myocardial infarction. The gut microbiota has been implicated in cardiometabolic disease but its relationship with subclinical coronary atherosclerosis is unknown. We identified 73 gut metagenomics species associated with coronary artery calcium score (CACS) in 8,973 SCAPIS participants without previous cardiovascular disease. Streptococcus associations were overrepresented and were validated in an independent case- control study together with eight non-Streptococcus spp. We further found enrichment for bacterial genes linked to amino acid and carbohydrate degradation functions. Gut Streptococcus spp. were associated with circulating biomarkers of inflammation and infection response, bile acids, androgenic steroids and sphingomyelins, and were associated with their homologous species in the oral cavity, which were in turn associated with oral pathologies. This study provides robust evidence of the association of Streptococcus spp., with subclinical atherosclerosis and markers of systemic inflammation and infection, calling for studies re-investigating the infectious hypothesis in atherosclerosis pathogenesis.Competing Interest StatementThe authors declare the following competing interests: S.P, N.N., A.E., J.B.H. and H.B.N. are employees for the company Clinical Microbiomics A/S, where the sample processing has been performed from DNA extraction to the estimations of relative abundance for the metagenomics species. J. Ä. has received lecture fees from Novartis and AstraZeneca, and served on advisory boards for AstraZeneca and Boerhinger Ingelheim, all unrelated to the present paper. PMN has received lecture fees from Novartis, Novo Nordisk, Amgen and Boerhinger Ingelheim unrelated to the present paper. The other authors declare no competing interests.Funding StatementThe main financial support for the study was from the European Research Council (ERC-2018-STG-801965 (TF); ERC-CoG-2014-649021 (MO-M) and ERC-STG-2015-679242 (JGS)). Further funding was also provided from the Swedish Research Council (VR 2019-01471 (TF), 2018-02784 (MO-M), 2018-02837 (MO-M), 2019-01015 (JÄ), 2020-00243 (JÄ), 2019-01236 (GE), 2017-02554 (JGS); and EXODIAB 2009-1039 (MO-M)); the Swedish Heart-Lung Foundation [HjÄrt-Lungfonden 20190505 (TF), 20200711 (MO-M), 20180343 (JÄ), 2019-0526 (JGS), 20200173 (GE)]; the A.L.F. governmental grant (2018-0148 (MO-M)); the Novo Nordisk Foundation (NNF20OC0063886 (MO-M)); the Swedish Diabetes Foundation (DIA 2018-375 (MO-M)); the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067 (MO-M)); Formas (2020-00989 (SA)); Göran Gustafsson foundantion [2016 (TF)]; and Axel and Signe Lagerman's foundation (TF), The main funding body of The Swedish CArdioPulmonary bioImage Study (SCAPIS) is the Swedish Heart-Lung Foundation. The study is also funded by the Knut and Alice Wallenberg Foundation; the Swedish Research Council and VINNOVA (Sweden's Innovation agency); the University of Gothenburg and Sahlgrenska University Hospital; Karolinska Institutet and Stockholm County Council; Linköping University and University Hospital; Lund University and Skåne University Hospital; Umeå University and University Hospital; and Uppsala University and University Hospital. The main funding body of Malmö Offspring Dental Study (MODS) was Oral Health Related Research by Region Skåne (OFRS 422361, OFRS 512951, OFRS 567711, OFRS 655561, OFRS 752071, OFRS 853031, OFRS 931171 and OFRS968144). The Malmö Offspring Study (MOS) has been funded by the Research Council of Sweden (VR 521-2013-2756 (PMN)), the Swedish Heart and Lung Foundation [HjÄrt-Lungfonden 20150427 (PMN)], and by funds (′ALF′) obtained from the local Region Skåne County Council (PMN). In addition, funding has been obtained from Ernhold Lundströms Stiftelse (LB). The computations and data handling were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala University (SNIC CENTRE) partially funded by the Swedish Research Council through grant agreement no. 2018-05973. The computations were performed using resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project SNIC sens2019512.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This investigation followed the principles expressed in the Declaration of Helsinki and was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten Dnr 2010-228-31M, Dnr. 2018/315). The Malmö Offspring Dental Study (MODS) was approved by the Regional Ethics committee (Regionala etikprövningsnÄmden, REPN) in Lund (Dnr 2013/761), which is part of the Malmö Offspring Study (MOS) with ethical approval from Regional Ethics committee (REPN) in Lund (Dnr 2012/594).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of individual data are limited due to the sensitive nature of the data and it can only be used with previous ethical approval. Therefore, the metagenomics sequences has been anonymized and they are available in ENA under accession code ′PRJEB51353′. A subset of anonymized metabolomics data (n=125) is available in MetaboLights under the study identifier ′MTBLS407′. However, all the data used in this work is available from the authors upon reasonable request and with previous written permission from the Swedish Ethical Review Authority and the SCAPIS Data Access Board. https://www.ebi.ac.uk/ena/browser/view/PRJEB51353?show=reads https://www.ebi.ac.uk/metabolights/MTBLS407